Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 91
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 16
MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vráblík
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 33
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions
Yangyang Li, Tianlei Zheng, Shu–Yuan Xiao, et al.
Liver International (2023) Vol. 43, Iss. 6, pp. 1170-1182
Open Access | Times Cited: 23
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
Ziyan Pan, Moutaz Derbala, Khalid Al‐Naamani, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 5, pp. 101512-101512
Open Access | Times Cited: 13
High‐Sensitivity C‐Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction‐Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography
Xiaodong Zhou, Qin‐Fen Chen, Giovanni Targher, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 10
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1178-1201
Closed Access | Times Cited: 10
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, et al.
Nature Medicine (2024)
Open Access | Times Cited: 10
Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
Jingli Gao, Yuhao Li, Yijun Zhang, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 5
Open Access | Times Cited: 9
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 7
The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis
Nenny Agustanti, Nanny Natalia Mulyani Soetedjo, Fachreza Aryo Damara, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 5, pp. 102780-102780
Closed Access | Times Cited: 17
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 7
Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
Xiaodong Zhou, Cuifang Xu, Qin‐Fen Chen, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3684-3695
Closed Access | Times Cited: 6
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
Ziwei Guo, Dongjie Wu, Richeng Mao, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle‐aged individuals with metabolic dysfunction
Alessandro Mantovani, Serena Pelusi, Sara Margarita, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 10, pp. 1093-1102
Open Access | Times Cited: 15
Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future
Feng Gao, Gang Chen, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 6, pp. 945-948
Open Access | Times Cited: 14
Iron biology
Lucia Del Vecchio, Domenico Girelli, Francesca Vinchi, et al.
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 9, pp. 1404-1415
Closed Access | Times Cited: 4
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
Giovanni Musso, Silvia Pinach, Filippo Mariano, et al.
Hepatology (2024)
Closed Access | Times Cited: 4
Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery
Gong Feng, Yu Han, Wah Yang, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 4
Nonalcoholic fatty liver disease and chronic kidney disease: random connections or two manifestations of metabolic syndrome?
Н. С. Карпунина, О. В. Хлынова
Experimental and Clinical Gastroenterology (2025), Iss. 8, pp. 123-130
Closed Access
Page 1 - Next Page

Scroll to top